About AccelevirDx
AccelevirDx is a company based in Baltimore (United States) founded in 2015. AccelevirDx offers products and services including ELISpot, FluoroSpot, Digital PCR, Flow Cytometry, and Next-Generation Sequencing. AccelevirDx operates in a competitive market with competitors including Chembio, Sedia Biosciences, Aldatu Biosciences, Chipcare and UrSure, among others.
- Headquarter Baltimore, United States
- SectorsHealthcare
- Email••••••••
- Website accelevirdx.com
- Social LinkedIn
- Latest Funding Round$600K (USD), Grant
Jul 2021
- Investors
Products & Services of AccelevirDx
AccelevirDx offers a comprehensive portfolio of products and services, including ELISpot, FluoroSpot, Digital PCR, Flow Cytometry, and Next-Generation Sequencing.
Assay for detecting immune responses in research.
Assay for monitoring cellular immune functions.
Technology for precise quantitation of targets.
Method for phenotyping and analyzing cells.
Service for advanced sequencing in virology.
Funding Insights of AccelevirDx
- Total Rounds 7
- Last Round Grant — $600,000
- First Round $2.26M
(Jun 2016)
- Investors Count 1
All 7 funding rounds of AccelevirDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in AccelevirDx
AccelevirDx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for AccelevirDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of AccelevirDx
3 dated milestones of AccelevirDx across 6 years, from founding to its latest funding, stage changes and deals.
- Founded AccelevirDx is founded.
- Funding First funding round of $2.3M.
- Funding Latest funding round, Grant, of $600K.
Competitors of AccelevirDx
AccelevirDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Chembio, Sedia Biosciences, Aldatu Biosciences, Chipcare and UrSure, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| chembio.com | 1986 | Medford, United States | – | 213 | Proprietary immunoassay platform is utilized for infectious disease diagnostics. | |
| sediabio.com | 2009 | Portland, United States | $284,998 | 33 | Point-of-care HIV diagnostic assays and surveillance tools are developed. | |
| aldatubio.com | 2014 | Boston, United States | – | – | Diagnostic tools for infectious diseases are developed using genotyping platforms. | |
| chipcare.ca | 2009 | Toronto, Canada | $11.1M | – | Develops a hand-held blood test device from a single drop of blood. | |
| ursureinc.com | 2015 | Boston, United States | – | – | Non-invasive urine test for HIV PrEP adherence monitoring is developed. | |
| labnow.com | 2005 | Austin, United States | $21.64M | – | Offers WBC counting point-of-care diagnostic systems for healthcare needs. | |
| pathwaydx.com | 2002 | Malibu, United States | – | – | Biomarker discovery platform and diagnostic assays were developed and licensed. | |
| calypte.com | 1988 | Portland, United States | – | – | Oral dipstick Immunoassay based HIV test products | |
| avioq.com | 2007 | Research, Australia | – | 53 | Avioq specializes in IVD product development, production, and contract services. |
Detailed competitors of AccelevirDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AccelevirDx
The website of AccelevirDx (accelevirdx.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▲ 381.2% vs previous month
Similar companies to AccelevirDx
10 companies that operate in the same segment as AccelevirDx (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AccelevirDx
AccelevirDx was founded in 2015 and raised its 1st funding round 1 year after it was founded.
AccelevirDx is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Developer of diagnostic assays for HIV. The assay detects ultra-rare analytes of HIV and other viral infections in the blood. The company uses ddPCR, qPCR, sequencing, and also culture-based methods to develop assays.
AccelevirDx's top competitors include Chembio, Aldatu Biosciences and Sedia Biosciences.
AccelevirDx offers ELISpot, FluoroSpot, Digital PCR, Flow Cytometry, and Next-Generation Sequencing.
AccelevirDx has 1 investor. Key investors include HHS.